Novartis announces that Fabio Sperandei assumes the position of President of Novartis Cyprus and Malta, with effect from February 1st, 2023 and responsibility for the Innovative Medicines business unit.

Fabio Sperandei holds a degree in Economics from La Sapienza University, Rome (Italy) and a master in Marketing after 9 months scholarship at University of Malaga (Spain).

He began his career in the consulting business as senior auditor in KPMG, before moving to the industrial sector where he travelled around the world as controller and financial / IT manager.

His career in the pharmaceutical industry began in 2004 at Sandoz (Novartis group) where he held positions of increased responsibility in finance, IT and commercial before moving to General Management roles. Within Novartis group Fabio lived and worked in 7 different countries and 2 continents. Sustained track record in business and portfolio transformation, digital innovation, product launches, business and cultural turnarounds.

Most recently he drove performance for patients also via artificial intelligence projects in South East Asia and UK, before moving to Cyprus in March 2021 as General Manager for the Pharma division for both Cyprus and Malta.